GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Short Interest

SELLAS Life Sciences Group (FRA:RXK3) Short Interest


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of SELLAS Life Sciences Group's Short Interest

For the Biotechnology subindustry, SELLAS Life Sciences Group's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Short Interest distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Short Interest falls into.



SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines